Geistlich Pharma, a family-owned Swiss company with its North American headquarters in Princeton, NJ, is a world leader in the field of biomaterials and medical devices.
Geistlich Pharma is also developing a tumor-cell selective agent, GP-2250, for cancers with high unmet needs. The drug candidate is selective for cancer cells through a novel mechanism of action focused on enzymes regulating the intracellular metabolism of cancer cells. Related to its MOA we have also seen (in vitro) decreases in cytokine release-an issue with CAR-T and bispecific antibody treatments.
GP-2250 is now in the clinic and Geistlich is committed to continued funding of the on-going Phase I trial, however, since oncology is not Geistlich’s core business, we are seeking a strategic and/or financial partner.
Geistlich Pharma is also developing a tumor-cell selective agent, GP-2250, for cancers with high unmet needs. The drug candidate is selective for cancer cells through a novel mechanism of action focused on enzymes regulating the intracellular metabolism of cancer cells. Related to its MOA we have also seen (in vitro) decreases in cytokine release-an issue with CAR-T and bispecific antibody treatments.
GP-2250 is now in the clinic and Geistlich is committed to continued funding of the on-going Phase I trial, however, since oncology is not Geistlich’s core business, we are seeking a strategic and/or financial partner.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
1851
Main Therapeutic Focus:
Oncology
Lead Product in Development:
GP-2250, a tumor-cell selective agent
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
